Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 601–700 of 1,001
5-hydroxymethylcytosine and gene activity in mouse intestinal differentiation
Uribe‐Lewis, S., Carroll, T., Menon, S., Nicholson, A. M., Manasterski, P. J., Winton, D. J., Buczacki, S. J. A., & Murrell, A. (2020) · Scientific Reports · doi:10.1038/s41598-019-57214-z · Cited by 28
EGFR‐vIII downregulated H2AZK4/7AC though the PI3K/AKT‐HDAC2 axis to regulate cell cycle progression
Zhao, H., Wang, Y., Yang, C., Zhou, J., Wang, L., Yi, K., Li, Y., Wang, Q., Shi, J. P., Kang, C., et al. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0260-7 · Cited by 28
Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1
Yang, J., Talibov, V., Peintner, S., Rhee, C., Poongavanam, V., Geitmann, M., Sebastiano, M. R., Simon, B., Hennig, J., Dobritzsch, D., et al. (2020) · ACS Omega · doi:10.1021/acsomega.9b03493 · Cited by 27
Zhang, S., Liu, Y., Zhou, X., Ou, M., Xiao, G., Li, F., Wang, Z., Wang, Z., Liu, L., & Zhang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.779235 · Cited by 27
Sirtuins, a key regulator of ageing and age-related neurodegenerative diseases
Bhatt, V., & Tiwari, A. K. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2057849 · Cited by 28
Tang, H., Liang, Y., Shen, H., Cai, S., Yu, M., Fan, H., Ding, K., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106112 · Cited by 27
Li, E., Choi, J., Sim, H., Kim, J.-H., Jun, J. H., Kyung, J., Ha, N., Kim, S., Ryu, K. H., Chung, S., et al. (2023) · BMB Reports · doi:10.5483/bmbrep.2022-0157 · Cited by 29
“Various kinds of pharmaceutical compounds for potential HD therapy have been reported so far (3).”
BackgroundPhysicochemical modifications of histones and their impact on epigenomics
Andreoli, F., & Río, A. D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.005 · Cited by 30
The Triple-Code Model for Pancreatic Cancer
Lomberk, G. A., & Urrutia, R. A. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.011 · Cited by 30
Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton
Hà, V. T. T., Kien, V. T., Binh, L. H., Tiến, V. Đ., My, N. T. T., Nam, N., Baltas, M., Hahn, H., Han, B. W., Thảo, Đ. T., et al. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.03.008 · Cited by 29
Ma, T., Huang, C. Z., Meng, X., Li, X., Zhang, Y., Ji, S., Li, J., Ye, M., & Liang, H. (2016) · Scientific Reports · doi:10.1038/srep25396 · Cited by 27
Hsp90 as a “Chaperone” of the Epigenome
Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 32
Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion
Zhang, Y., Guo, Y., Gough, S. M., Zhang, J., Vann, K. R., Li, K., Cai, L., Shi, X., Aplan, P. D., Wang, G. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17098-4 · Cited by 29
New Role for Histone Deacetylase 9 in Atherosclerosis and Inflammation
Smith, J. D. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304295 · Cited by 28
“Because protein acetylation controls many features of cell physiology and proliferation, there are many HDAC and sirtuin inhibitors in use in the laboratory as well as in the clinical pipeline, with 2 drugs, vorinostat and romidepsin, approved for oncology, and a host of other drugs in clinical trials for a range of d…”
MethodBromodomains: Are Readers Right for Epigenetic Therapy?
Conway, S. J. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300221t · Cited by 32
Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression
Moreno-Yruela, C., Fass, D. M., Cheng, C., Herz, J., Olsen, C. A., & Haggarty, S. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00281 · Cited by 27
Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
Vatapalli, R. J., Rossi, A. P., Chan, H. M., & Zhang, J. (2024) · Epigenomics · doi:10.1080/17501911.2024.2430169 · Cited by 31
Erban, T., Harant, K., Chalupnikova, J., Kocourek, F., & Stará, J. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.09.016 · Cited by 27
“However, the regulation of alternative splicing was also influenced by epigenetic modifications, such as methylation and acetylation, through effects on the chromatin structure and histonemodifications [24,25].”
BackgroundZacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 30
Molecular Genetics and New Medication Strategies for Opioid Addiction
Hurd, Y. L., & O’Brien, C. P. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030352 · Cited by 28
“Moreover, multiple families of proteins are involved in adding (writers), recognizing (readers) or removing (erasers) epigenetic marks (66, 67).”
BackgroundPotluri, V., Shandil, R., Gavara, R., Sambasivam, G., Campo, B., Wittlin, S., & Narayanan, S. (2020) · Malaria Journal · doi:10.1186/s12936-020-03421-3 · Cited by 24
Vreese, R. D., Depetter, Y., Verhaeghe, T., Desmet, T., Benoy, V., Haeck, W., Bosch, L. V. D., & D’hooghe, M. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02625c · Cited by 26
Williams, D. E., Izard, F., Arnould, S., Dalisay, D. S., Tantapakul, C., Maneerat, W., Matainaho, T. K., Julien, E., & Andersen, R. J. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b02569 · Cited by 26
Chen, X., Zhao, S., Wu, Y., Chen, Y., Lu, T., & Zhu, Y. (2016) · RSC Advances · doi:10.1039/c6ra21271a · Cited by 26
Histone Adduction and Its Functional Impact on Epigenetics
Galligan, J. J., & Marnett, L. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00379 · Cited by 27
Quantitative Analysis and Discovery of Lysine and Arginine Modifications
Galligan, J. J., Kingsley, P. J., Wauchope, O. R., Mitchener, M. M., Camarillo, J. M., Wepy, J. A., Harris, P. S., Fritz, K. S., & Marnett, L. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04105 · Cited by 28
Molecular advances in cutaneous T-cell lymphoma
Torres, A. N. B., Najidh, S., Tensen, C. P., & Vermeer, M. H. (2018) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.2018.007 · Cited by 27
“Histones not only play roles in the packaging, replication, and repair of DNA but also regulate gene expression.(28,29) Both DNA and histones are subjected to chemical (known as epigenetic) modifications that direct changes in chromatin architecture.”
BackgroundDiscovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors
Lu, W., Xiong, H., Chen, Y., Wang, C., Zhang, H., Xu, P., Han, J., Xiao, S.-H., Ding, H., Chen, Z., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.048 · Cited by 27
Yang, F., Shan, P., Zhao, N., Ge, D., Zhu, K., Jiang, C., Li, P., & Zhang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.027 · Cited by 26
Huber, T. D., Clinger, J. A., Liu, Y., Xu, W., Miller, M. D., Phillips, G. N., & Thorson, J. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00943 · Cited by 27
Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery
Denis, I., Bahhaj, F. E., Collette, F. M., Delatouche, R., Gueugnon, F., Pouliquen, D., Pichavant, L., Héroguez, V., Grégoire, M., Bertrand, P., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.037 · Cited by 29
Marx, C., Marx-Blümel, L., Lindig, N., Thierbach, R., Hoelzer, D., Becker, S., Wittig, S., Lehmann, R., Slevogt, H., Heinzel, T., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0541-1 · Cited by 25
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin
Souto, J. A., Sarno, F., Nebbioso, A., Papulino, C., Álvarez, R., Lombino, J., Perricone, U., Padova, A., Altucci, L., & de Lera, Á. R. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00312 · Cited by 25
Kaundal, B., Kushwaha, A. C., Srivastava, A. K., Karmakar, S., & Choudhury, S. R. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01177k · Cited by 25
Muddassir, M., Soni, K. V., Sangani, C. B., AlArifi, A. S., Afzal, M. F., Abduh, N. A. Y., Duan, Y., & Bhadja, P. (2020) · RSC Advances · doi:10.1039/d0ra07971e · Cited by 29
Small Molecule Gated Split-Tyrosine Phosphatases and Orthogonal Split-Tyrosine Kinases
Camacho-Soto, K., Castillo‐Montoya, J., Tye, B., Ogunleye, L. O., & Ghosh, I. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5080745 · Cited by 26
Yan, H., Tian, S., Slager, S. L., & Sun, Z. (2016) · Epigenomics · doi:10.2217/epi-2016-0053 · Cited by 27
Chemical genetics approaches for selective intervention in epigenetics
Runcie, A. C., Chan, K.-H., Zengerle, M., & Ciulli, A. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.031 · Cited by 26
“Firstly, the difficulty in generating single-target selectivity is magnified in epigenetic systems, where many domains are clustered in large families with highly conserved substrate-binding sites [6].”
BackgroundLi, Z., Oganesyan, D., Mooney, R., Rong, X., Christensen, M. J., Shahmanyan, D., Perrigue, P. M., Benetatos, J., Tsaturyan, L., Aramburo, S., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.013 · Cited by 27
“, DNA methylases/demethylases, histone methyltransferases/demethylases, acetyltransferases/ deacetylases, and RNAi) has led to advances in basic as well as translational science, including clinical development (Arrowsmith et al., 2012).”
BackgroundInfluentialWang, G., Wang, J., Du, L., Li, F., & To, S. S. T. (2016) · Nutrition and Cancer · doi:10.1080/01635581.2016.1225105 · Cited by 25
“Instead of using many drugs together in combination therapy, it would be ideal to design drugs that could simultaneously act on many of the aberrant genetic pathways (9).”
BackgroundPharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
Lu, R., & Wang, G. G. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00241 · Cited by 27
Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2018) · Biomolecules · doi:10.3390/biom8030061 · Cited by 27
“Readers are epi-enzymes whose function is to recognize certain modifications and their patterns on histones [7].”
BackgroundTotal Synthesis of Trapoxin A, a Fungal HDAC Inhibitor from Helicoma ambiens
Servatius, P., & Kazmaier, U. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01569 · Cited by 28
Inflammation, advancing age and nutrition
Rahman, I., & Bagchi, D. (2014) · Elsevier eBooks · doi:10.1016/c2011-0-08000-6 · Cited by 12
“strategies against epigenetic modifier enzymes for the treatment of metabolic disorders [49–51].”
MethodBronner, S. M., Murray, J. M., Romero, F. A., Lai, K. W., Tsui, V., Cyr, P., Beresini, M. H., Boenig, G. D. L., Chen, Z., Choo, E. F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01372 · Cited by 25
Selective targeting of epigenetic reader domains
Greschik, H., Schüle, R., & Günther, T. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1303474 · Cited by 26
Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
Pandey, S., Djibo, R., Darracq, A., Calendo, G., Zhang, H., Henry, R. A., Andrews, A. J., Baylin, S. B., Madžo, J., Najmanovich, R., et al. (2022) · Cancers · doi:10.3390/cancers14143340 · Cited by 25
“However, these efforts may take years before approval and may have limited effects outside of a restricted patient population [12].”
BackgroundAmini, N., Hivechi, A., Asadpour, S., Ebrahimzadeh, K., Kargozar, S., Gholipourmalekabadi, M., Nasrolahi, A., Ghasemian, M., Shafaat, A., Mozafari, M., et al. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01292-0 · Cited by 27
“PyMOL was also employed to demonstrate better collagenchemokine modes of interactions for docking and molecular dynamics simulation assessment [38, 39].”
MethodBasavarajappa, B. S., & Subbanna, S. (2024) · Epigenomics · doi:10.2217/epi-2023-0428 · Cited by 26
BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses
Kokkola, T., Suuronen, T., Pesonen, M., Filippakopoulos, P., Salminen, A., Jarho, E. M., & Lahtela-Kakkonen, M. K. (2015) · ChemBioChem · doi:10.1002/cbic.201500272 · Cited by 28
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors
Taddei, M., Cini, E., Giannotti, L., Giannini, G., Battistuzzi, G., Vignola, D., Vesci, L., & Cabri, W. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.072 · Cited by 28
Wang, G., Wang, J., Du, L., & Li, F. (2015) · BioMed Research International · doi:10.1155/2015/856349 · Cited by 24
“Instead of using many drugs together in a combination therapy, it would be ideal to make drugs that act on many of the aberrant genetic pathways simultaneously [21].”
BackgroundRetractedAntigenic Variation in Plasmodium falciparum
Petter, M., & Duffy, M. F. (2015) · Results and problems in cell differentiation · doi:10.1007/978-3-319-20819-0_3 · Cited by 29
“Mainly children under the age of five are affected by severe disease and account for 78 % of malaria deaths (Arrowsmith et al. 2012).”
BackgroundInfluentialNovel approaches to map small molecule–target interactions
Kapoor, S., Waldmann, H., & Ziegler, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.020 · Cited by 35
Current discovery strategies for hepatocellular carcinoma therapeutics
Dai, Q., Zhang, C., Yuan, Z., Sun, Q., & Jiang, Y. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696769 · Cited by 26
“according to their structure [126,127]: Short-chain fatty acids”
BackgroundYuan, Q., Zhang, H., Pan, Z., Ling, X., Wu, M., Gui, Z., Chen, J., Peng, J., Liu, Z., Tan, Q., et al. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.114147 · Cited by 24
Rodríguez-Carlos, A., Jacobo-Delgado, Y. M., Santos-Mena, A. O., & Rivas-Santiago, B. T. (2021) · Peptides · doi:10.1016/j.peptides.2021.170527 · Cited by 25
Synthesis and Assays of Inhibitors of Methyltransferases
Cai, X.-C., Kapilashrami, K., & Luo, M. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.01.009 · Cited by 32
“Therefore, targeting these epigenetic modifiers can be a potential therapeutic strategy aimed at restoring the normal chromatin state of relevant genes (Arrowsmith et al., 2012).”
BackgroundBurridge, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3943 · Cited by 24
Bayer, T., Chakrabarti, A., Lancelot, J., Shaik, T. B., Hausmann, K., Melesina, J., Schmidtkunz, K., Marek, M., Erdmann, F., Schmidt, M., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800238 · Cited by 23
Compromised epigenetic robustness in cancer: fueling evolution, exposing weakness
Wilson, T. S., & Scaffidi, P. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.001 · Cited by 25
Waybright, J. M., Clinkscales, S. E., Barnash, K. D., Budziszewski, G. R., Rectenwald, J. M., Chiarella, A. M., Norris-Drouin, J. L., Cholensky, S. H., Pearce, K. H., Herring, L. E., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00429 · Cited by 25
Ali, F., Almuhaimeed, A., Khalid, M., Alshanbari, H. S., Masmoudi, A., & Alsini, R. A. I. (2024) · Methods · doi:10.1016/j.ymeth.2024.04.004 · Cited by 23
Malhotra, R., & Olsson, H. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1000865 · Cited by 26
“Examples of such epigenetic mechanisms include DNA methylation, histone modification and RNA interference [23].”
BackgroundRan, T., Zhang, Z., Liu, K., Lu, Y., Li, H., Xu, J., Xiong, X., Zhang, Y., Xu, A., Lü, S., et al. (2015) · Molecular BioSystems · doi:10.1039/c4mb00723a · Cited by 23
The polar warhead of a TRIM 24 bromodomain inhibitor rearranges a water‐mediated interaction network
Liu, J., Li, F., Bao, H., Jiang, Y., Zhang, S., Ma, R., Gao, J., Wu, J., & Ruan, K. (2017) · FEBS Journal · doi:10.1111/febs.14041 · Cited by 23
Kwon, S., Cho, C. H., Kwon, Y., Lee, E. S., & Park, J. (2017) · Scientific Reports · doi:10.1038/srep45968 · Cited by 23
Negmeldin, A. T., & Pflum, M. K. H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.033 · Cited by 23
“HDAC proteins require either metal ions or NAD as cofactors for catalysis.(8) The eleven metal-dependent HDAC isoforms are grouped as classes I, II, or IV, depending on their size, cellular localization, and homology to other HDAC proteins.”
BackgroundHistone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia
Desjardins, D. M., Liu, Y., Crosson, C. E., & Ablonczy, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162596 · Cited by 25
Wigle, T. J., & Copeland, R. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.035 · Cited by 24
“Methyllysine is an abundant histone modification, and not surprisingly a diversity of methyl-lysine reader domains exist [5 ].”
BackgroundOstrop, J., Zwiggelaar, R. T., Pedersen, M. T., Gerbe, F., Bösl, K., Lindholm, H. T., Díez-Sánchez, A., Parmar, N., Radetzki, S., von Kries, J. P., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.618552 · Cited by 28
“Several hundred epigenetic modification enzymes contribute to writing, erasing, and reading the epigenetic code (Arrowsmith et al., 2012).”
BackgroundSelf-citationKong, B., Zhu, Z., Li, H., Hong, Q., Wang, C., Ma, Y., Zheng, W., Jiang, F., Zhang, Z., Ran, T., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113953 · Cited by 23
Peng, X., Yu, Z., Surineni, G., Deng, B., Zhang, M., Li, C., Sun, Z., Pan, W., Liu, Y., Liu, S., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2201408 · Cited by 23
RetractedMinireview: Conversing With Chromatin: The Language of Nuclear Receptors
Biddie, S. C., & John, S. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1247 · Cited by 23
Bahhaj, F. E., Dekker, F. J., Martinet, N., & Bertrand, P. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.017 · Cited by 23
Feng, T., Li, D., Wang, H., Zhuang, J., Liu, F., Bao, Q., Lei, Y., Chen, W., Zhang, X., Xu, X., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.013 · Cited by 22
Reddy, D. R., Ballante, F., Zhou, N., & Marshall, G. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.032 · Cited by 23
Ahmad, M., Aga, M. A., Bhat, J. A., Kumar, B. N., Rouf, A., Capalash, N., Mintoo, M. J., Kumar, A., Mahajan, P., Mondhe, D. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00322 · Cited by 25
Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from Trypanosoma brucei
Xiao, Y., Wu, X., Zhang, J., Zhang, X., Xu, C., Liao, S., & Tu, X. (2017) · Biochemical Journal · doi:10.1042/bcj20170619 · Cited by 23
Guidi, A., Saccoccia, F., Gennari, N., Gimmelli, R., Nizi, E., Lalli, C., Paonessa, G., Papoff, G., Bresciani, A., & Ruberti, G. (2018) · Parasites & Vectors · doi:10.1186/s13071-018-3268-8 · Cited by 22
“cer cells, have already been discovered [31].”
Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy
Zhu, H., Wei, T., Cai, Y., & Jin, J. (2020) · Molecules · doi:10.3390/molecules25030578 · Cited by 25
“Based on sequence or structure similarity, human BRD-containing proteins are divided into eight families [19].”
BackgroundShirbhate, E., Patel, P., Patel, V. K., Veerasamy, R., Sharma, P. C., & Rajak, H. (2020) · Future Oncology · doi:10.2217/fon-2020-0385 · Cited by 25
Chen, Y., Ouyang, S.-S., Chen, Y., Li, P., Xu, H., & Zhu, S. (2020) · Aging · doi:10.18632/aging.103768 · Cited by 22
Feng, T., Wang, H., Su, H. L., Lu, H., Yu, L., Zhang, X., Sun, H., & You, Q. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.06.009 · Cited by 23
Building a KATalogue of acetyllysine targeting and function
Downey, M., & Baetz, K. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv045 · Cited by 27
“(KDAC)-encoding genes have been implicated in a wide variety of human diseases, and therapeutics are increasingly being used or developed to target these enzymes [2].”
BackgroundLobo-Silva, J., Cabral, F. J., Amaral, M. S., Miyasato, P. A., de Freitas, R. P., Pereira, A. S. A., Khouri, M. I., Barbosa, M. M. F., Ramos, P. I. P., Leite, L. C. C., et al. (2020) · Parasites & Vectors · doi:10.1186/s13071-020-4000-z · Cited by 23
The BRPF1 bromodomain is a molecular reader of di-acetyllysine
Obi, J. O., Lubula, M. Y., Cornilescu, G., Henrickson, A., McGuire, K., Evans, C. M., Phillips, M., Boyson, S. P., Demeler, B., Markley, J. L., et al. (2020) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2020.05.001 · Cited by 21
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer
Loras, A., Segovia, C., & Ruiz-Cerdá, J. L. (2021) · Cancers · doi:10.3390/cancers13112719 · Cited by 23
Evidence that HDAC7 acts as an epigenetic “reader” of AR acetylation through NCoR-HDAC3 dissociation
Zhang, Y., Andrade, R. E., Hanna, A. A., & Pflum, M. K. H. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.008 · Cited by 23
Song, Y., Liu, X., Stielow, J. B., de Hoog, S., & Li, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966457 · Cited by 22
Noguchi‐Yachide, T., Sakai, T., Hashimoto, Y., & Yamaguchi, T. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.022 · Cited by 21
Fragment-based drug discovery and protein–protein interactions
Turnbull, A. P., Boyd, S., & Walse, B. (2014) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28428 · Cited by 29
“68 71–75 In these studies, the fragment hits interact with conserved water molecules and residues by mimicking the AcK head group, whilst lipophilic parts of the fragments engage with hydrophobic side chains.”
Simard, J. R., Plant, M., Emkey, R., & Yu, V. L. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2012.481 · Cited by 21
Virtual screening in small molecule discovery for epigenetic targets
Li, G., Yang, L., Yuan, Y., Zou, J., Cao, Y., Yang, S., Xiang, R., & Xiang, M. (2014) · Methods · doi:10.1016/j.ymeth.2014.11.010 · Cited by 21
Geddes, J. R., & Miklowitz, D. J. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.205 · Cited by 22
Novel 64Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases
Meng, Q., Li, F., Jiang, S., & Li, Z. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400191z · Cited by 21
1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity
Zhao, X., Tan, Q., Zhang, Z., & Zhao, Y. C. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1084-z · Cited by 22
“Inhibition of HDACs has been indicated as a unique mechanism for cancer chemotherapy, and over 12 small-molecule HDAC inhibitors are currently in clinical trials for different cancers (Arrowsmith et al., 2012; Zhang et al., 2010).”
BackgroundSchistosome Sirtuins as Drug Targets
Lancelot, J., Cabezas‐Cruz, A., Caby, S., Marek, M., Schultz, J., Romier, C., Sippl, W., Jung, M., & Pierce, R. J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.24 · Cited by 24
Epigenetic modulation by inorganic metal complexes
Leung, C., Liu, L., Leung, K., & Ma, D. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.03.014 · Cited by 24
Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer
Celano, M., Mio, C., Sponziello, M., Verrienti, A., Bulotta, S., Durante, C., Damante, G., & Russo, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.036 · Cited by 22
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.